Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

Delayed Quote. Delayed  - 06/23 03:33:19 pm
509.004 USD   -3.33%
03:43p MARKETS RIGHT N : US stocks open slightly lower
12:23p REGENERON PHARM : Details Royalty Agreement with Novartis for Canaki..
06/22 NASDAQ 100 MOVE : Ca, regn
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/19/2017 06/20/2017 06/21/2017 06/22/2017 06/23/2017 Date
471.67(c) 495.33(c) 522.02(c) 526.53(c) 509.004 Last
807 575 2 134 851 1 743 114 1 843 555 128 833 Volume
+2.56% +5.02% +5.39% +0.86% -3.33% Change
More quotes
Financials ($)
Sales 2017 5 475 M
EBIT 2017 2 170 M
Net income 2017 1 018 M
Finance 2017 2 110 M
Yield 2017 -
Sales 2018 6 136 M
EBIT 2018 2 571 M
Net income 2018 1 294 M
Finance 2018 2 842 M
Yield 2018 -
P/E ratio 2017 59,75
P/E ratio 2018 47,07
EV / Sales2017 9,84x
EV / Sales2018 8,66x
Capitalization 55 965 M
More Financials
Company
Regeneron Pharmaceuticals, Inc. operates as a biopharmaceutical company.It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.The company involves in marketing medicines for eye diseases, colorectal cancer and a rare inflammatory... 
More about the company
Surperformance© ratings of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on REGENERON PHARMACEUTICALS
03:43p MARKETS RIGHT NOW : US stocks open slightly lower
12:23p REGENERON PHARMACEUTICALS : Details Royalty Agreement with Novartis for Canakinu..
06/22 REGENERON PHARMACEUTICALS : Patent Issued for Method for Detecting the Replaceme..
06/22 REGENERON PHARMACEUTICALS : Patent Issued for Stabilized Formulations Containing..
06/22 REGENERON PHARMACEUTICALS : Recent Findings from Regeneron Pharmaceuticals Inc. ..
06/22 NASDAQ 100 MOVERS : Ca, regn
06/22 REGENERON PHARMACEUTICALS : Details Royalty Agreement with Novartis for Canakinu..
06/21 MARKETS RIGHT NOW : Stocks open slightly higher
06/21 REGENERON PHARMACEUTICALS : Recognized on "The Civic 50" List of the Most Commun..
06/21 REGENERON PHARMACEUTICALS : Today's Research Reports on Stocks to Watch: Regener..
More news
Sector news : Bio Therapeutic Drugs
01:15pDJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
06/14 JOHNSON & JOHNSON : flu drug succeeds in mid-stage trial
More sector news : Bio Therapeutic Drugs
Latest Tweets
01:49pCanaccord Genuity Reiterates $484.00 Price Target for Regeneron Pharmaceutica.. 
10:11a3 Things In Biotech You Should Learn Today: June 23, 2017  
04:51aRegeneron Pharmaceuticals's outperform rating reiterated at Leerink Swann.  
06/22$REGN We've been in this for a while, some nice extra juice this week
1
06/22#Regeneron: How High Can It Go?  
More tweets
Qtime:77
News from SeekingAlpha
04:11a 3 THINGS IN BIOTECH YOU SHOULD LEARN : June 23, 2017
06/22 Cantos Could Make Ilaris A Blockbuster
06/22 Regeneron clarifies canakinumab royalty deal with Novartis
06/22 3 THINGS IN BIOTECH YOU SHOULD LEARN : June 22, 2017
06/22 Market Is Divided Between Growth And Value - Cramer's Mad Money (6/21/17)
Advertisement
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Full-screen chart
Technical analysis trends REGENERON PHARMAC...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 461 $
Spread / Average Target -12%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Leonard S. Schleifer President, Chief Executive Officer & Director
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
George Damis Yancopoulos Director & Chief Scientific Officer
Neil Stahl Executive VP-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTIC..42.20%55 965
AMGEN18.88%127 827
CELGENE CORPORATION15.49%104 381
GILEAD SCIENCES-1.58%92 098
VERTEX PHARMACEUTICALS83.02%33 756
ACTELION23.47%30 485
More Results